Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5- HT(2C) receptors

Synapse

Volumn 35, Issue 2, 2000, Pages 144-150

  Egan, Christina ^a   Grinde, Ellinor ^a   Dupre, Ann ^a   Roth, Bryan L ^b   Hake, Michael ^b   Teitler, Milt ^a   Herrick Davis, Katharine ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT(2A) receptors; 5 HT(2C) receptors; Intrinsic activity; K(L) K(H) ratio; Revised ternary complex; Serotonin; Ternary complex

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; 5 METHOXYTRYPTAMINE; BUFOTENINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LISURIDE; LYSERGIDE; PHOSPHATIDYLINOSITOL; QUIPAZINE; RADIOLIGAND; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; CELL LINE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; MODEL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; SEROTONINERGIC SYSTEM;

ANIMALS; CELL LINE; COMPUTER SIMULATION; GTP-BINDING PROTEINS; INOSITOL PHOSPHATES; KINETICS; PHOSPHATIDYLINOSITOLS; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION; TRANSFECTION; TRITIUM;

EID: 0033987382     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K     Document Type: Article

References (11)

1. De Lean A, Stadel JM, Lefkowitz RJ. 1980. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255:7108-7117.
2. Egan CT, Herrick-Davis K, Teitler M. 1998. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90.
3. Herrick-Davis K, Egan C, Teitler M. 1997. Activating mutations of the serotonin 5-HT2C receptor. J Neurochem 69:1138-1144.
4. Kent RS, De Lean A, Lefkowitz RJ. 1980. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14-23.
5. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. 1993. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
6. Leonhardt S, Gorospe E, Hoffman BJ, Teitler M. 1992. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Mol Pharmacol 42:328-335.
7. 3H-DOB (4-bromo-2,5-dimethoxy-phenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194-199.
8. Roth BL, Choudary MS, Khan N, Uluer AZ. 1997. High-affinity agonist binding is not sufficient for agonist intrinsic activity at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280:576-583.
9. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. 1993. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
10. Teitler M, Leonhardt S, Weisberg EL, Hoffman BJ. 1990. 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. Mol Pharmacol 38:594-598.
11. Teitler M, Lyon RA, Davis KH, Glennon RA. 1987. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand. Biochem Pharmacol 36:3265-3271.